Maithili Shrikhande
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Role not yet determined Is this you? Add your title
Also affiliated: University of Bern (2000); St. John's University (2018–2020); Heidelberg University (2003)
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
M Shrikhande's research primarily investigates the utilization and costs associated with treating patients who have Type-2 Diabetes and Cardiovascular Disease. This work specifically examines the use of Sodium Glucose Cotransporter-2 Inhibitors and Glucagon Like Peptide-1 Receptor Agonists in patient care. Shrikhande has contributed to a publication in 2024 detailing these aspects.
With a career h-index of 2 and 180 total citations across 9 publications, Shrikhande has collaborated with researchers at the University of Arkansas for Medical Sciences, including Laura E. Gressler, Jacob T. Painter, and Christopher Johnson, with whom they share single publications.
Metrics
- h-index: 2
- Publications: 10
- Citations: 185
Selected Publications
-
EE490 Utilization and Costs of Patients With Type-2 Diabetes and Cardiovascular Disease Treated With Sodium Glucose Cotransporter-2 Inhibitors and Glucagon Like Peptide-1 Receptor Agonists (2024)
Collaboration Network
Top Collaborators
- EE490 Utilization and Costs of Patients With Type-2 Diabetes and Cardiovascular Disease Treated With Sodium Glucose Cotransporter-2 Inhibitors and Glucagon Like Peptide-1 Receptor Agonists
- EE490 Utilization and Costs of Patients With Type-2 Diabetes and Cardiovascular Disease Treated With Sodium Glucose Cotransporter-2 Inhibitors and Glucagon Like Peptide-1 Receptor Agonists
- EE490 Utilization and Costs of Patients With Type-2 Diabetes and Cardiovascular Disease Treated With Sodium Glucose Cotransporter-2 Inhibitors and Glucagon Like Peptide-1 Receptor Agonists
- EE490 Utilization and Costs of Patients With Type-2 Diabetes and Cardiovascular Disease Treated With Sodium Glucose Cotransporter-2 Inhibitors and Glucagon Like Peptide-1 Receptor Agonists
Similar Researchers
Based on overlapping research topics